{"entity":{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","aka":[],"tldr":"Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials.","summary":"Jennifer Wargo led the 2018 Science paper showing that gut microbiome composition predicts response to PD-1 blockade in melanoma patients, alongside parallel work from Gustave Roussy and Chicago that founded microbiome-directed immuno-oncology. She led one of the first randomised neoadjuvant immunotherapy trials in melanoma and co-leads the International Neoadjuvant Melanoma Consortium. Her laboratory now studies diet, fibre and microbiome modulation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma"}],"tags":["melanoma","microbiome","neoadjuvant"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["fmt-pd1-refractory-melanoma-pitt"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genomic Medicine and Surgical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Melanoma","Microbiome and immunotherapy","Neoadjuvant immunotherapy","Surgical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma"}],"papers":[{"title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","journal":"Science","year":2018,"doi":"10.1126/science.aan4236"},{"title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0197-1"}]},"route":"/people/jennifer-wargo/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/"}]}}